Clinical Trials Logo

Filter by:
NCT ID: NCT05184283 Terminated - Clinical trials for Hepatocellular Carcinoma

Utilization of MAsS in Patients Undergoing LT for HCC

Start date: June 16, 2022
Phase:
Study type: Observational

The aim of this study is to determine the effects of liver transplantation and standard immunosuppression on body composition in patients with compensated cirrhosis and hepatocellular carcinoma.

NCT ID: NCT05182151 Terminated - Parkinson Disease Clinical Trials

Effect of Istradefylline Treatment on Behavioral Measures of Apathy in Parkinson's Disease.

Start date: July 29, 2022
Phase:
Study type: Observational

Apathy is defined as a lack of feeling, emotion, interest, or concern. Apathy also involves reduction or loss of motivation and goal-directed behavior. Clinically significant apathy, where meaningful activities are given up and quality of life is diminished, is common in people with Parkinson's disease (PD). Many individuals with Parkinson's disease experiencing fluctuations in the severity of their movement problems and medication "off" time. "Off" time refers to periods of the day between doses of PD medication when your motor symptoms (e.g., tremor, stiffness, slowness, walking problems, etc.) are worse and interfere with your ability to complete tasks of daily living. The investigational drug, Istradefylline, is an FDA-approved medication to treat motor fluctuations and "off" time in PD. The purpose of this study is to investigate whether people with Parkinson's disease (PD) who are treated with istradefylline (ISD) show improvements in motivation and apathy over a 12-week period. Specifically, we wish to see whether people with PD who are treated with ISD engage in more physical and recreational activities, such as hobbies and other interests.

NCT ID: NCT05181995 Terminated - PTSD Clinical Trials

Safety and Efficacy of 50 mg NYX-783 QD vs. Placebo in PTSD

Start date: December 13, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

A Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of 50 mg NYX-783 Once Daily Compared to Placebo in Participants with Post-Traumatic Stress Disorder (PTSD)

NCT ID: NCT05181540 Terminated - Hodgkin Lymphoma Clinical Trials

A Study of the Effects of AB-205 in Patients With Lymphoma Undergoing Autologous Hematopoietic Cell Transplantation

E-CELERATE
Start date: February 21, 2022
Phase: Phase 3
Study type: Interventional

High-dose chemotherapy followed by blood stem cell transplantation is administered to lymphoma patients with an intention to cure. However, high-dose chemotherapy simultaneously causes damage to healthy tissues that frequently result in severe complications that lead to hospitalization and can be life threatening. These severe complications involve the blood, immune, gastro-intestinal systems, and other vital organs. The purpose of this study is to determine if experimental therapy AB-205 (study drug) can prevent or reduce the occurrence and duration of the severe chemotherapy related complications when compared to placebo in patients with lymphoma undergoing treatment with high-dose chemotherapy and blood stem cell transplantation. All patients, whether treated with AB-205 or placebo, will receive standard preventive and supportive care therapies.

NCT ID: NCT05179057 Terminated - Clinical trials for Adenovirus Infection

Posoleucel (ALVR105) for the Treatment of Adenovirus Infection in Pediatric and Adult Participants Receiving Standard of Care Following Allogeneic Hematopoietic Cell Transplantation

Start date: April 26, 2022
Phase: Phase 3
Study type: Interventional

This study will assess the safety and efficacy of Posoleucel for the treatment of adenovirus (AdV) infection in pediatric and adult allo-HCT recipients receiving standard of care (SoC).

NCT ID: NCT05179005 Terminated - Rib Fractures Clinical Trials

RibFix Advantageā„¢ Post-Market Follow-Up

ZB-PIONEER
Start date: April 20, 2023
Phase:
Study type: Observational

To confirm safety, performance, and clinical benefits for the use of RibFix Advantageā„¢ in the fixation, stabilization, and fusion of rib fractures and osteotomies of normal and osteoporotic bone

NCT ID: NCT05177770 Terminated - Prostate Cancer Clinical Trials

Study of SRF617 With AB928 (Etrumadenant) and AB122 (Zimberelimab) in Patients With Metastatic Castration Resistant Prostate Cancer

Start date: January 17, 2022
Phase: Phase 2
Study type: Interventional

This trial will look at the safety and preliminary efficacy of SRF617 in combination with etrumadenant and zimberelimab in patients with metastatic castration-resistant prostate cancer (mCRPC).

NCT ID: NCT05177718 Terminated - Multiple Sclerosis Clinical Trials

Natalizumab and Chronic Inflammation

Start date: September 16, 2022
Phase: Phase 4
Study type: Interventional

In this study the investigators will assess the ability of Natalizumab, a medication given to treat multiple sclerosis (MS), to restore blood brain barrier integrity and repair subtle leakages of the blood brain barrier (BBB).

NCT ID: NCT05177328 Terminated - Atopic Dermatitis Clinical Trials

Targeted Investigation of Microbiome Elimination

TIME-1
Start date: July 18, 2022
Phase: Phase 1
Study type: Interventional

The purpose of this study is to examine the pharmacokinetics or survival of new product containing commensal infection fighting bacteria, on the skin of patients with Atopic Dermatitis (AD), after a single application.

NCT ID: NCT05176717 Terminated - Clinical trials for Retinitis Pigmentosa

Study to Evaluate the Efficacy Safety and Tolerability of QR-421a in Subjects With RP Due to Mutations in Exon 13 of the USH2A Gene With Early to Moderate Vision Loss (Celeste)

Start date: December 15, 2021
Phase: Phase 2/Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy safety and tolerability of QR-421a administered via intravitreal injection (IVT) in subjects with Retinitis Pigmentosa (RP) due to mutations in exon 13 of the USH2A gene with early to moderate vision loss.